D. Hammers, T. J. Atkinson, B. C. Dalley, K. Suhrie, B. Beardmore, L. Burrell, K. Horn, K. Rasmussen, N. Foster, K. Duff, J. Hoffman
{"title":"非痴呆社区老年人18f -氟替他莫摄取与rban表现的关系","authors":"D. Hammers, T. J. Atkinson, B. C. Dalley, K. Suhrie, B. Beardmore, L. Burrell, K. Horn, K. Rasmussen, N. Foster, K. Duff, J. Hoffman","doi":"10.1080/13854046.2016.1278039","DOIUrl":null,"url":null,"abstract":"Abstract Objective: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been used extensively for clinical care and in research for patients with mild cognitive impairment and Alzheimer’s disease (AD); however, relatively few studies have evaluated the relationship between RBANS performance and AD imaging biomarkers. The purpose of the current study was to evaluate the association between a relatively new amyloid positron emission tomography imaging biomarker and performance on the RBANS. Methods: Twenty-seven nondemented community-dwelling adults over the age of 65 underwent 18F-Flutemetamol amyloid– positron emission tomography imaging, along with cognitive testing using the RBANS and select behavioral measures. Partial correlation coefficients were used to identify relationships between the imaging and behavioral markers. Results: After controlling for age and education, amyloid deposition and RBANS Indexes of Immediate Memory, Delayed Memory, and Total Scale score were significantly correlated (p’s < .001, r’s = −.73 to −.77, d’s = 2.13–2.39), with greater amyloid burden being associated with lower RBANS scores. The Delayed Memory Index was particularly highly associated with 18F-Flutemetamol binding (r2 = .59, p < .001, d = 2.39). Neither 18F-Flutemetamol binding nor RBANS performance was significantly correlated with levels of depression, subjective cognitive difficulties, or premorbid intellect. Conclusions: Because of the limited use of amyloid imaging in clinical settings due to high cost and lack of reimbursement, these findings suggest that in particular RBANS Delayed Memory Index may be a cost-efficient tool to identify early signs of AD pathology, and its use may enlighten clinical decision-making regarding potential progression to dementia due to AD.","PeriodicalId":197334,"journal":{"name":"The Clinical neuropsychologist","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"Relationship between 18F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults\",\"authors\":\"D. Hammers, T. J. Atkinson, B. C. Dalley, K. Suhrie, B. Beardmore, L. Burrell, K. Horn, K. Rasmussen, N. Foster, K. Duff, J. Hoffman\",\"doi\":\"10.1080/13854046.2016.1278039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objective: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been used extensively for clinical care and in research for patients with mild cognitive impairment and Alzheimer’s disease (AD); however, relatively few studies have evaluated the relationship between RBANS performance and AD imaging biomarkers. The purpose of the current study was to evaluate the association between a relatively new amyloid positron emission tomography imaging biomarker and performance on the RBANS. Methods: Twenty-seven nondemented community-dwelling adults over the age of 65 underwent 18F-Flutemetamol amyloid– positron emission tomography imaging, along with cognitive testing using the RBANS and select behavioral measures. Partial correlation coefficients were used to identify relationships between the imaging and behavioral markers. Results: After controlling for age and education, amyloid deposition and RBANS Indexes of Immediate Memory, Delayed Memory, and Total Scale score were significantly correlated (p’s < .001, r’s = −.73 to −.77, d’s = 2.13–2.39), with greater amyloid burden being associated with lower RBANS scores. The Delayed Memory Index was particularly highly associated with 18F-Flutemetamol binding (r2 = .59, p < .001, d = 2.39). Neither 18F-Flutemetamol binding nor RBANS performance was significantly correlated with levels of depression, subjective cognitive difficulties, or premorbid intellect. Conclusions: Because of the limited use of amyloid imaging in clinical settings due to high cost and lack of reimbursement, these findings suggest that in particular RBANS Delayed Memory Index may be a cost-efficient tool to identify early signs of AD pathology, and its use may enlighten clinical decision-making regarding potential progression to dementia due to AD.\",\"PeriodicalId\":197334,\"journal\":{\"name\":\"The Clinical neuropsychologist\",\"volume\":\"20 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Clinical neuropsychologist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/13854046.2016.1278039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Clinical neuropsychologist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/13854046.2016.1278039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12
摘要
【摘要】目的:神经心理状态评估重复性测试(rban)已广泛应用于轻度认知障碍和阿尔茨海默病(AD)患者的临床护理和研究中;然而,相对较少的研究评估了rban性能与AD成像生物标志物之间的关系。本研究的目的是评估一种相对较新的淀粉样蛋白正电子发射断层成像生物标志物与rban表现之间的关系。方法:27名65岁以上的无痴呆社区居民接受了18f -氟地他莫淀粉样蛋白正电子发射断层扫描成像,同时使用rban进行认知测试和选择行为测量。偏相关系数用于识别影像学和行为标志物之间的关系。结果:在控制年龄和受教育程度后,淀粉样蛋白沉积与即时记忆、延迟记忆、总量表评分的rban指数呈显著相关(p < 0.001, r =−)。73 ~−。77, d 's = 2.13-2.39),淀粉样蛋白负荷越大,rban评分越低。延迟记忆指数与18f -氟替他莫结合高度相关(r2 = 0.59, p < 0.001, d = 2.39)。18f -氟替他莫结合和rban表现与抑郁水平、主观认知困难或病前智力均无显著相关性。结论:由于高成本和缺乏报销,淀粉样蛋白成像在临床环境中的使用有限,这些研究结果表明,特别是RBANS延迟记忆指数可能是一种经济有效的工具,可以识别阿尔茨海默病病理的早期迹象,它的使用可能启发临床决策,判断阿尔茨海默病可能进展为痴呆。
Relationship between 18F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults
Abstract Objective: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been used extensively for clinical care and in research for patients with mild cognitive impairment and Alzheimer’s disease (AD); however, relatively few studies have evaluated the relationship between RBANS performance and AD imaging biomarkers. The purpose of the current study was to evaluate the association between a relatively new amyloid positron emission tomography imaging biomarker and performance on the RBANS. Methods: Twenty-seven nondemented community-dwelling adults over the age of 65 underwent 18F-Flutemetamol amyloid– positron emission tomography imaging, along with cognitive testing using the RBANS and select behavioral measures. Partial correlation coefficients were used to identify relationships between the imaging and behavioral markers. Results: After controlling for age and education, amyloid deposition and RBANS Indexes of Immediate Memory, Delayed Memory, and Total Scale score were significantly correlated (p’s < .001, r’s = −.73 to −.77, d’s = 2.13–2.39), with greater amyloid burden being associated with lower RBANS scores. The Delayed Memory Index was particularly highly associated with 18F-Flutemetamol binding (r2 = .59, p < .001, d = 2.39). Neither 18F-Flutemetamol binding nor RBANS performance was significantly correlated with levels of depression, subjective cognitive difficulties, or premorbid intellect. Conclusions: Because of the limited use of amyloid imaging in clinical settings due to high cost and lack of reimbursement, these findings suggest that in particular RBANS Delayed Memory Index may be a cost-efficient tool to identify early signs of AD pathology, and its use may enlighten clinical decision-making regarding potential progression to dementia due to AD.